CRISPR/Cas9 gene-edited regulatory T-cell therapies (Seattle Children's Hospital/Casebia)

N/A

Report date: 2025/03/19 08:59:16

Base Information

Drug NameCRISPR/Cas9 gene-edited regulatory T-cell therapies (Seattle Children's Hospital/Casebia)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSeattle Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesCasebia Therapeutics LlcSeattle Children'S Hospital
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A